- Home
- VCIG vs LPCN Comparison
VCIG vs LPCN Comparison
Compare VCIG & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VCIG | LPCN |
|---|---|---|
| Founded | 2013 | 1997 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 13.8M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | VCIG | LPCN |
|---|---|---|
| Price | $0.57 | $3.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 3.2M | 47.6K |
| Earning Date | 01-21-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.98 | N/A |
| Revenue | ★ $32,903,041.00 | $4,322,693.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.88 | ★ N/A |
| Revenue Growth | ★ 24.77 | N/A |
| 52 Week Low | $0.80 | $2.52 |
| 52 Week High | $1,344.00 | $5.50 |
Technical Indicators
Market Signals| Indicator | VCIG | LPCN |
|---|---|---|
| Relative Strength Index (RSI) | 29.12 | 51.42 |
| Support Level | $0.89 | $3.05 |
| Resistance Level | $1.28 | $3.39 |
| Average True Range (ATR) | 0.14 | 0.15 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 3.70 | 34.69 |
Price Performance
Historical ComparisonAbout VCIG VCI Global Limited
VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology development, solutions and consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment, which focuses on listing solutions, investor relations, and boardroom strategies consultancy.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.